Brought to you by 
Epigenomics completes €5.18mm stock sale
17 Mar 2009
Executive Summary
Epigenomics (molecular diagnostics for cancer) grossed €5.18mm ($6.7mm) through the sale of 2.7mm new shares at €1.94 each (a 10% premium) to a subsidiary of BB Medtech AG and funds managed by Abingworth LLP. Now the investors each hold 14.9% and 11.1% stakes in the company, respectively. Epigenomics will use the funds to complete development and initiate commercialization of its blood test for colorectal cancer.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epigenomics completes €5.18mm stock sale
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice